Mark J. O’Connor

21.3k total citations · 5 hit papers
119 papers, 13.7k citations indexed

About

Mark J. O’Connor is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Mark J. O’Connor has authored 119 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Oncology, 83 papers in Molecular Biology and 29 papers in Genetics. Recurrent topics in Mark J. O’Connor's work include DNA Repair Mechanisms (63 papers), PARP inhibition in cancer therapy (61 papers) and BRCA gene mutations in cancer (17 papers). Mark J. O’Connor is often cited by papers focused on DNA Repair Mechanisms (63 papers), PARP inhibition in cancer therapy (61 papers) and BRCA gene mutations in cancer (17 papers). Mark J. O’Connor collaborates with scholars based in United Kingdom, United States and Singapore. Mark J. O’Connor's co-authors include Alan Lau, Johann S. de Bono, Andrew Tutt, Alan Ashworth, Timothy A. Yap, Graeme C.M. Smith, Yves Pommier, David S. Boss, James Carmichael and Jan H.M. Schellens and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Mark J. O’Connor

114 papers receiving 13.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Andrew Tutt, Alan Lau et al. profile →
Targeting the DNA Damage Response in Cancer

2015 1.1k citations Mark J. O’Connor profile →
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

2006 977 citations Nuala McCabe, Nicholas C. Turner et al. Cancer Research profile →
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

2008 762 citations Sven Rottenberg, Janneke E. Jaspers et al. profile →
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

2016 540 citations Mark J. O’Connor et al. profile →

Peers

Countries citing papers authored by Mark J. O’Connor

Since Specialization

Citations

This map shows the geographic impact of Mark J. O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. O’Connor more than expected).

Fields of papers citing papers by Mark J. O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. O’Connor. The network helps show where Mark J. O’Connor may publish in the future.

Co-authorship network of co-authors of Mark J. O’Connor

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. O’Connor. A scholar is included among the top collaborators of Mark J. O’Connor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. O’Connor. Mark J. O’Connor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial 2024 ·Targeted Oncology ·Erika Hamilton, Gerald S. Falchook, Judy S. Wang, Siqing Fu, Amit M. Oza, (unknown), Sanjeev Kumar, Lone H. Ottesen, Ganesh Mugundu, Elza C. de Bruin, Mark J. O’Connor, Suzanne F. Jones, David R. Spigel, Bob T. Li	3
2	Understanding tumour growth variability in breast cancer xenograft models identifies PARP inhibition resistance biomarkers 2024 ·npj Precision Oncology ·(unknown), Josep V. Forment, (unknown), Dimitris Polychronopoulos, (unknown), Andreas Bender, Violeta Serra, Mark J. O’Connor, James Yates, Krishna C. Bulusu	2
3	Initial Experience With Intercostal Insertion of an Extravascular ICD Lead Compatible With Existing Pulse Generators 2023 ·Circulation Arrhythmia and Electrophysiology ·Martin C. Burke, Reinoud E. Knops, Vivek Y. Reddy, Johan D. Aasbo, Michael Husby, (unknown), Mark J. O’Connor, Rick Sanghera, (unknown), (unknown), Adrián Ebner	2
4	Identifying and overcoming a mechanism of resistance to WEE1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells 2022 ·European Journal of Gynaecological Oncology ·(unknown), John P. Thomson, Graeme R. Grimes, Anderson T. Wang, Michael Churchman, Mark J. O’Connor, Charlie Gourley, David W. Melton	11
5	Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition 2022 ·Cancer Research Communications ·(unknown), Alessandro Galbiati, Joshua Armenia, Giuditta Illuzzi, James Hall, (unknown), Daniel Barrell, Miika Ahdesmäki, Mark J. O’Connor, Elisabetta Leo, Josep V. Forment	11
6	Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress 2021 ·Nucleic Acids Research ·(unknown), (unknown), Francisco Muñoz‐Martínez, (unknown), (unknown), Christelle de Renty, Mark J. O’Connor, Josep V. Forment, Yaron Galanty, Stephen P. Jackson	35
7	Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress 2019 ·Cancer Research ·Lucy A. Young, (unknown), Christelle de Renty, Margaret H. Veldman-Jones, Thierry Dorval, Zena Wilson, D. I. Jones, Deborah Lawson, Rajesh Odedra, Apolinar Maya‐Mendoza, Corinne Reimer, Jiří Bártek, Alan Lau, Mark J. O’Connor	54
8	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells 2017 ·Molecular Cancer Therapeutics ·Ahrum Min, Seock‐Ah Im, Hyemin Jang, Seongyeong Kim, Miso Lee, (unknown), Yaewon Yang, Hee Jun Kim, Kyung-Hun Lee, Jin Won Kim, Tae‐Yong Kim, Do‐Youn Oh, (unknown), Alan Lau, Mark J. O’Connor, Yung‐Jue Bang	105
9	PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors 2017 ·Molecular Cancer Research ·Leslie A. Parsels, David Karnak, Joshua D. Parsels, Qiang Zhang, (unknown), Zachery R. Reichert, Daniel Wahl, Jonathan Maybaum, Mark J. O’Connor, Theodore S. Lawrence, Meredith A. Morgan	98
10	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models 2016 ·Cancer Research ·Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, Rajesh Odedra, H. Shelton Brown, Janneke E. Jaspers, (unknown), Charlotte Knights, Bastiaan Evers, Attilla Ting, Robert H. Bradbury, Marina Pajic, Sven Rottenberg, Jos Jonkers, (unknown), Niall M.B. Martin, Keith W. Caldecott, Alan Lau, Mark J. O’Connor	60
11	Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment 2014 ·Clinical Cancer Research ·Kishan A.T. Naipal, Nicole S. Verkaik, Najim Ameziane, Carolien H. M. van Deurzen, Petra ter Brugge, Matty Meijers, Anieta M. Sieuwerts, John W.M. Martens, Mark J. O’Connor, Harry Vrieling, Jan H.J. Hoeijmakers, Jos Jonkers, Roland Kanaar, Johan P. de Winter, Maaike P.G. Vreeswijk, Agnes Jager, Dik C. van Gent	124
12	ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation 2013 ·Clinical Cancer Research ·(unknown), Sajjad Muhammad, Elizabeth Rosenberg, Jason M. Beckta, Nicholas C.K. Valerie, Mary Tokarz, Bret R. Adams, Alison F. Wagner, Ashraf Khalil, Donna Gilfor, Sarah E. Golding, Sumitra Deb, (unknown), Alan Lau, Mark J. O’Connor, Kevin S. Choe, Luis F. Parada, Sang Kyun Lim, Nitai D. Mukhopadhyay, Kristoffer Valerie	150
13	RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib 2013 ·Molecular Cancer Therapeutics ·Ahrum Min, Seock‐Ah Im, Young‐Kwang Yoon, Sang‐Hyun Song, (unknown), Hyung-Seok Hur, Hwang‐Phill Kim, Kyung-Hun Lee, Sae‐Won Han, Do‐Youn Oh, Tae‐You Kim, Mark J. O’Connor, Woo Ho Kim, Yung‐Jue Bang	109
14	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors 2012 ·Cancer Discovery ·Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, (unknown), James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg	388
15	Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft 2011 ·Molecular Cancer Therapeutics ·Joana M. Senra, Brian A. Telfer, (unknown), Cian M. McCrudden, David G. Hirst, Mark J. O’Connor, Stephen R. Wedge, Ian J. Stratford	155
16	ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors 2010 ·Molecular Cancer Therapeutics ·Chris T. Williamson, Huong Muzik, Ali G. Turhan, Alberto Zamò, Mark J. O’Connor, D. Gwyn Bebb, Susan P. Lees‐Miller	147
17	Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts 2010 ·Clinical Cancer Research ·(unknown), Jessica N. McAlpine, Hui Xue, Jun Guan, Gavin Ha, (unknown), (unknown), Alan Lau, Aaron Cranston, Mark J. O’Connor, David G. Huntsman, Yuzhuo Wang, C. Blake Gilks	52
18	Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin 2009 ·Cancer Research ·Trevor Hay, James R. Matthews, (unknown), Alan Lau, Aaron Cranston, Anders O.H. Nygren, Anthony Douglas-Jones, Graeme C.M. Smith, Niall M.B. Martin, Mark J. O’Connor, Alan R. Clarke	94
19	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion 2009 ·Molecular Cancer Therapeutics ·Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie, Isa M. Hussaini, Mark Frigerio, Xiaoling Cockcroft, (unknown), Marc Hummersone, Laurent Rigoreau, Keith Menear, Mark J. O’Connor, Lawrence F. Povirk, Timothy Van Meter, Kristoffer Valerie	285
20	Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition breakdown → 2006 ·Cancer Research ·Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth	977

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact